Startseite Quality indicators and specifications for key analytical-extranalytical processes in the clinical laboratory. Five years’ experience using the Six Sigma concept
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Quality indicators and specifications for key analytical-extranalytical processes in the clinical laboratory. Five years’ experience using the Six Sigma concept

  • Ma Antònia Llopis EMAIL logo , Gloria Trujillo , Ma Isabel Llovet , Ester Tarrés , Mercè Ibarz , Carme Biosca , Rosa Ruiz , Ma Jesus Alsina Kirchner , Virtudes Alvarez , Glòria Busquets , Ma Vicenta Doménech , Carme Figueres , Joana Minchinela , Rosa Ma Pastor , Carmen Perich , Carmen Ricós , Mireia Sansalvador und Margarita Simón Palmada
Veröffentlicht/Copyright: 31. Januar 2011
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background: The results of 5 years of experience (2004–2008) with process-based quality management using quality indicators for key laboratory processes (analytic and extra-analytic) in a group of clinical laboratories affiliated with the Catalan Health Institute are presented. Our purpose was to analyze the evolution of the indicators, identify processes that require corrective measures, and obtain specifica tions that are more robust than the preliminary ones proposed in a previous study by the same group.

Methods: The yearly average was recorded for each indicator in each laboratory, the yearly interlaboratory median was calculated, and the changes occurring were studied to determine their continuity in the 5-year period. For each indicator, the average of the yearly medians was calculated and the results transformed to the Six Sigma scale to estimate the degree of control over the related process. It was suggested to establish the yearly interlaboratory median as the desirable specification for each indicator.

Results: The medians for most indicators were stable during the period studied. Thus, the specifications proposed in the first study were considered robust in these cases. The Six Sigma statistic provided added value in this study because it enabled detection of processes that should be improved, in which case the specifications proposed were considered provisional despite their stability. After identifying processes that have the greatest impact on patient safety, the group set a specification of 0%, regardless of the actual specification obtained, although the members are conscious of the difficulty in attaining this level of quality. Certain processes that are in a period of change obtained specifications that are considered in a phase of consolidation.

Conclusions: The results for indicators related with sample collection indicate that the process is stable and well controlled. However, based on the results for Hemolyzed serum sample, the group saw the need for installing centrifuges in all phlebotomy centers and established a recommendation to unify the system for measuring hemolysis. The indicator External control exceeds acceptance limit clearly highlighted the need to rigorously monitor the analytic phase of the clinical laboratory. The values obtained for the indicator Reports from referred tests exceed delivery time show that there is considerable deviation regarding the expected report delivery time, whereas for in-house laboratory reports, delivery time is satisfactory.


Corresponding author: Dra. Ma Antònia Llopis, Laboratori Clínic Barcelonès Nord i Vallès Oriental, Pça. de la Medicina, s/n, ES-08911-Badalona, Spain

Received: 2010-6-30
Accepted: 2010;-9-25
Published Online: 2011-01-31
Published in Print: 2011-03-01

©2011 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Editorial
  2. Biomarkers of neurodegenerative diseases
  3. Reviews
  4. CSF biomarkers in neurodegenerative diseases
  5. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
  6. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease
  7. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease
  8. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease
  9. Parkinson's disease – the continuing search for biomarkers
  10. α-Synuclein in Parkinson disease and other neurodegenerative disorders
  11. S100B protein in neurodegenerative disorders
  12. Inflammatory and structural biomarkers in acute traumatic spinal cord injury
  13. Homocysteine: a biomarker in neurodegenerative diseases
  14. Editorial
  15. ROMA or death: advances in epithelial ovarian cancer diagnosis
  16. Review
  17. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays
  18. General Clinical Chemistry and Laboratory Medicine
  19. Quality indicators and specifications for key analytical-extranalytical processes in the clinical laboratory. Five years’ experience using the Six Sigma concept
  20. Determination of oxidative and occupational stress in palliative care workers
  21. Effect of cigarette smoking on plasma homocysteine concentrations
  22. Erythrocyte membrane protein analysis by sodium dodecyl sulphate-capillary gel electrophoresis in the diagnosis of hereditary spherocytosis
  23. Evaluation of hematological parameters on admission for the prediction of 7-day in-hospital mortality in a large trauma cohort
  24. Platelet function testing in hirudin and BAPA anticoagulated blood
  25. Evaluation of the iChem® Velocity™ Urine Chemistry Analyzer in a hospital routine laboratory
  26. Crystalluria: prevalence, different types of crystals and the role of infrared spectroscopy
  27. Cancer Diagnostics
  28. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
  29. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population
  30. Cardiovascular Diseases
  31. APOA5 −1131T/C polymorphism is associated with coronary artery disease in a Chinese population: a meta-analysis
  32. Assessment of the nickel-albumin binding assay for diagnosis of acute coronary syndrome
  33. Letters to the Editor
  34. AGER gene -374T>A (rs1800624) polymorphism is not associated with the severity of non-diabetic coronary artery disease in Han Chinese
  35. Some lessons learned from using medium scale genotyping techniques in pharmacogenetic research
  36. Improved neopterin ELISA kit: a good compromise between HPLC results and clinical practice
  37. Cross-reactivity of 25-hydroxy vitamin D2 from different commercial immunoassays for 25-hydroxy vitamin D: an evaluation without spiked samples
  38. Modulated human maternal and premature neonatal erythrocyte membrane enzyme activities in relation to the mode of delivery: in vitro restoration with L-Carnitine
Heruntergeladen am 7.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.067/html?lang=de
Button zum nach oben scrollen